Radiosurgery for Brain Tumors

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 386

Special Issue Editor


E-Mail Website
Guest Editor
Department of Medical Physics, Haaglanden Medical Center, 2262 BA Leidschendam, The Netherlands
Interests: photon and proton radiotherapy; radiosurgery; linac-based stereotactic radiotherapy multiple brain metastases

Special Issue Information

Dear Colleagues,

The incidence of cancer is increasing worldwide. As a noninvasive alternative to surgery, radiosurgery uses high-energy X-rays or protons to destroy tumors. As one of the treatment modalities, radiosurgery plays a crucial role in managing malignant brain tumors. Radiosurgery can also be used for the effective treatment of benign brain tumors such as meningiomas or pituitary adenoma.

Stereotactic radiosurgery (SRS) uses many precisely focused radiation beams for the accurate targeting of tumors while minimizing damage to the surrounding organs at risk, such as healthy brain tissue, brain stem, chiasm, optic nerves, eyes, the cochlea, and pituitary gland. Nowadays, magnetic resonance imaging (MRI) has significantly improved the delineation of brain tumors and has allowed for progress to be made in terms of irradiation using magnetic resonance linac (MRL).

We cordially invite you to submit your cutting-edge research and review articles to this Special Issue, which aims to encompass new research articles and timely reviews on all aspects of brain tumors’ radiosurgery treatment with photons or protons.

Dr. Anna Petoukhova
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiosurgery with photons and protons
  • stereotactic radiosurgery (SRS)
  • brain tumors
  • gliomas
  • meningioma
  • pituitary adenoma
  • magnetic resonance imaging (MRI)
  • magnetic resonance linac (MRL)

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 333 KiB  
Article
Patterns of Recurrence After Postoperative Stereotactic Radiotherapy for Brain Metastases
by Jeroen A. Crouzen, Anna L. Petoukhova, Martijn Hakstege, Elise E. M. W. van Schaik, Rishi D. S. Nandoe Tewarie, Rob J. A. Nabuurs, Maaike J. Vos, Melissa Kerkhof, Thijs van der Vaart, Johan A. F. Koekkoek, Rogier E. Hagenbeek, Fatih M. Yildirim, Lisette M. Wiltink, Noëlle C. M. G. van der Voort van Zyp, Mandy Kiderlen, Marike L. D. Broekman, Mirjam E. Mast and Jaap D. Zindler
Cancers 2025, 17(9), 1557; https://doi.org/10.3390/cancers17091557 (registering DOI) - 3 May 2025
Abstract
Background/Objectives: Neurosurgical resection is the standard treatment for large brain metastases (BMs). Postoperative stereotactic radiotherapy (SRT) is used to reduce local recurrence (LR) but does not always prevent leptomeningeal disease (LMD). This study aims to analyze patterns of tumor recurrence and to identify [...] Read more.
Background/Objectives: Neurosurgical resection is the standard treatment for large brain metastases (BMs). Postoperative stereotactic radiotherapy (SRT) is used to reduce local recurrence (LR) but does not always prevent leptomeningeal disease (LMD). This study aims to analyze patterns of tumor recurrence and to identify opportunities for the further improvement of treatment efficacy. Methods: We included 147 patients who underwent resection and SRT for BMs. The distance between the resection cavity target volume and the new tumor growth was calculated. Cox regression analyses were used to assess associations of LMD with various patient characteristics. Results: Median survival after postoperative SRT was 14 months (IQR 6–30) with a 3-year actuarial survival rate of 21%. LR occurred in 20/147 patients (14%). After total resection, LR occurred in 21% of patients after 3 years of follow-up compared to 36% after subtotal resection. Marginal LR occurred in 5/147 patients (3%). LMD was found in 21/147 patients (14%; 3-year actuarial rate, 26%), and it was found more commonly in patients with resected cerebellar metastases (23%; 3-year actuarial rate, 46%) compared to those with cerebral metastases (11%; 3-year actuarial rate 17%) (HR 2.54, 95% CI 1.07–6.04, p = 0.034). Conclusions: This study examined patterns of recurrence after postoperative radiotherapy and its implications for radiation dose, radiation field size, and treatment sequence. Local control was high after total resection. Radiation field size appeared adequate given the low incidence of marginal recurrences. Patients with cerebellar metastases showed an increased risk of LMD, underscoring the need for preventive measures, particularly preoperative SRT. Full article
(This article belongs to the Special Issue Radiosurgery for Brain Tumors)
Back to TopTop